Christina Thomas
Physician Assistant · Salt Lake City, UTNPI 1588216840
Payments from drug & device makers
Across 157 payments — averaging $21.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$836
- Johnson & Johnson$335
- Supernus Pharmaceuticals, Inc.$326
- Teva Pharmaceuticals USA, Inc.$299
- Otsuka America Pharmaceutical, Inc.$254
- Neurocrine Biosciences, Inc.$217
- plus $1K from 13 others
What the payments were for
- Food & beverage$3,355100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 34 | $836 |
| Johnson & Johnson | 16 | $335 |
| Supernus Pharmaceuticals, Inc. | 7 | $326 |
| Teva Pharmaceuticals USA, Inc. | 18 | $299 |
| Otsuka America Pharmaceutical, Inc. | 12 | $254 |
| Neurocrine Biosciences, Inc. | 9 | $217 |
| Alkermes, Inc. | 9 | $212 |
| Axsome Therapeutics, Inc. | 10 | $193 |
| Lundbeck LLC | 8 | $171 |
| E.r. Squibb & Sons, L.L.C. | 15 | $160 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $110 |
| Idorsia Pharmaceuticals US Inc | 4 | $73 |
| Biogen | 2 | $38 |
| Vanda Pharmaceuticals Inc. | 1 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Indivior Inc. | 1 | $25 |
| Alfasigma USA, Inc. | 1 | $22 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $15 |
| Bausch Health US, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$249
How this compares
$3,355 in reported general payments places this provider in the 90th percentile of 1,543 physician assistant providers in Utah.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 15 | $23,793 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 16 | $2,120 |
| Lamotrigine | 33 | $677 |
| Duloxetine Hcl | 16 | $633 |
| Clonazepam | 27 | $563 |
| Risperidone | 16 | $334 |
| Quetiapine Fumarate | 17 | $311 |
| Mirtazapine | 14 | $285 |
| Hydroxyzine Pamoate | 12 | $213 |
| Zolpidem Tartrate ErZolpidem Tartrate | 12 | $163 |
| Escitalopram Oxalate | 12 | $112 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $836 | $23,79315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,543 physician assistant providers in Utah.
Other physician assistant in Salt Lake City
- Jill EricksonSalt Lake City$179K
- Natalie BeeSalt Lake City$63K
- Samuel ShewanSalt Lake City$22K
- Christy MaSalt Lake City$17K
- Shane FarrSalt Lake City$14K
- Gintare DaileySalt Lake City$13K
- Corey DahlSalt Lake City$13K
- David JonesSalt Lake City$12K
- Corbin WoodSalt Lake City$12K
- Amy HillierSalt Lake City$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.